Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: Pilot study

CNS Spectrums

Volumn 19, Issue 4, 2014, Pages 316-323

  Morozova, Margarita A ^a   Lepilkina, Taisiya A ^a   Rupchev, Georgy E ^a   Beniashvily, Allan G ^a   Burminskiy, Denis S ^a   Potanin, Sergey S ^a   Bondarenko, Evgeny V ^b   Kazey, Vasily I ^b   Lavrovsky, Yan ^c   Ivachtchenko, Alexandre V ^c,d  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^b Avineuro LLC   (Russian Federation)

^c Avineuro Pharmaceuticals Inc   (United States)

^d Chemical Diversity Research Institute   (Russian Federation)

Author keywords

5HT6 receptor antagonist; add on; clinical effects; schizophrenia

Indexed keywords

3 SULFONYL PYRAZOLO[1,5 A]PYRIMIDINE; APOMORPHINE; AVN 211; BUSPIRONE; CHLORPROMAZINE; CHLORPROTHIXENE; DONEPEZIL; FENOBAM; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; RUFINAMIDE; SCOPOLAMINE; SEROTONIN 6 ANTAGONIST; SULPIRIDE; TACRINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL; 3-SULFONYL-PYRAZOLO(1,5-A)PYRIMIDINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SCOPOLAMINE BROMIDE; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADD ON THERAPY; ADULT; ALERTNESS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BOURDOHN TEST; CALGARY DEPRESSION RATING SCALE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTINUOUS ATTENTION TASK; CONTROLLED STUDY; DIGIT SYMBOL CODING; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG WITHDRAWAL; ELEVATED PLUS MAZE TEST; EXPERIMENTAL COGNITIVE TEST; HUMAN; IN VIVO STUDY; MALE; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PREPULSE INHIBITION OF ACOUSTIC STARTLE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPONSE TIME; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; WECHSLER INTELLIGENCE SCALE; ANIMAL; ATTENTION; BAGG ALBINO MOUSE; CLINICAL TRIAL; COGNITION; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; MAZE TEST; MIDDLE AGED; PILOT STUDY; PREPULSE INHIBITION; PSYCHOLOGY; REACTION TIME; STARTLE REFLEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; BEHAVIOR, ANIMAL; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; COGNITION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; MALE; MAZE LEARNING; MICE; MICE, INBRED BALB C; MIDDLE AGED; PILOT PROJECTS; PIPERIDINES; PREPULSE INHIBITION; PYRAZOLES; PYRIMIDINES; REACTION TIME; RECEPTORS, SEROTONIN; REFLEX, STARTLE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCOPOLAMINE HYDROBROMIDE; SEROTONIN ANTAGONISTS; TACRINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906534688     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000394     Document Type: Article

References (52)

1. Mazure CM, Nelson JC, Jatlow PI, Bowers MB. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Res. 1992; 41: 147-154.
2. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009; 14: 429-447.
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(Suppl 2): 1-56.
4. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006; 32(2): 214-219.
5. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007; 64: 633-647. (Pubitemid 46878665)
6. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry. 1991; 48(3): 239-246.
7. Tandon R, Ribeiro SCM, DeQuardo JR, et al. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry. 1993; 34(7): 495-497. (Pubitemid 23337734)
8. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001; 158(2): 176-184. (Pubitemid 32116511)
9. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry. 2004; 55(10): 1013-1022. (Pubitemid 38581917)
10. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, ''just the facts'' 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010; 122(1-3): 1-23.
11. Mortimer AM. Cognitive function in schizophrenia-do neuroleptics make a difference? Pharmacol Biochem Behav. 1997; 56(4): 789-795. (Pubitemid 27189765)
12. Bilder RM. Neurocognitive impairment in schizophrenia and how it affects treatment options. Can J Psychiatry. 1997; 42(3): 255-264. (Pubitemid 27257123)
13. Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry. 2001; 49(4): 374-384. (Pubitemid 32182368)
14. Kane J. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010; 12(3): 345-357.
15. Phan SV, Kreys TJ. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy. 2011; 31(10): 1017-1030.
16. Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res. 2012; 134(2-3): 202-206.
17. Raveendranathan D, Shivakumar V, Jayaram N, Rao NP, Venkatasubramanian G. Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health. 2012; 15(2): 147-148.
18. Morozova MA, Beniashvili AG, Rupchev GE, et al. Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits. Zh Nevrol Psikhiatr Im S S Korsakova. 2008; 108(11): 28-35 [in Russian].
19. Morozova MA, Beniashvili AG, Lepilkina TA, Rupchev GE. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. Psychiatr Danub. 2012; 24(2): 159-166.
20. Chen X, Liu W, Wang L, et al. Psychosocial functioning and cognitive deficits are not associated with membranebound catechol-O-methyltransferase deoxyribonucleic acid methylation in siblings of patients with schizophrenia. J Nerv Ment Dis. 2012; 200(11): 941-945.
21. Weiser M, Heresco-Levy U, Davidson M, et al. A multicenter, add-on randomized controlled trial of lowdose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012; 73(6): 728-734.
22. Khodaie-Ardakani MR, Seddighi S, Modabbernia A, et al. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebocontrolled study. J Psychiatr Res. 2013; 47(4): 472-478.
23. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol. 2012; 13(8): 1572-1586.
24. Egerton A, Stone JM. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr Pharm Biotechnol. 2012; 13(8): 1500-1512.
25. Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A. Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl). 2012; 220(3): 481-494.
26. Olincy A, Freedman R. Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the a7 nicotinic receptor. Handb Exp Pharmacol. 2012; 213: 211-232.
27. McKinzie DL, Bymaster FP. Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol. 2012; 213: 233-265.
28. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol. 2007; 78: 133-164.
29. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, ''just the facts'': what we know in 2008. Part 3: neurobiology. Schizophr Res. 2008; 106(2-3): 89-107.
30. Pae CU. Role of the cholinesterase inhibitors in the treatment of schizophrenia. Expert Opin Investig Drugs. 2013; 22(3): 293-298.
31. Yakel JL. Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflugers Arch. 2013; 465(4): 441-450.
32. Romero G, Sanchez E, Pujol M, et al. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol. 2006; 148(8): 1133-1143. (Pubitemid 44223019)
33. Rosse G, Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem. 2010; 10: 207-221.
34. Glennon RA. Higher-end serotonin receptors: 5-HT5, 5 HT6 and 5HT7. J Med Chem. 2003; 46(14): 2795-2812.
35. West PJ, Marcy VR, Marino MJ, Schaffhauser H. Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience. 2009; 164(2): 692-701.
36. de Foubert G, O'Neill MJ, Zetterstrom TS. Acute onset by 5 HT6 receptor activation on rat brain brain-derived neurotrophic factor and activity regulated cytoskeletalassociated protein mRNA expression. Neuroscience. 2007; 147: 778-785. (Pubitemid 46990655)
37. Morairty SR, Hedley L, Flores J, Martin R, Kilduff TS. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep. 2008; 31(1): 34-44.
38. Yun HM, Rhim H. The serotonin-6 receptor as a novel therapeutic target. Exp Neurobiol. 2011; 20(4): 159-168.
39. Saegis Pharmaceuticals Completes Phase IIa Clinical Study of SGS518. http://www.thefreelibrary.com/Saegis1Pharmaceuticals1Completes1Phase1IIa1 Clinical1Study1of1SGS518. -a0139781616.
40. Lundbeck's Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer's disease. May 29, 2012. http://investor.lundbeck.com/releasedetail.cfm? ReleaseID5677436.
41. Okun I, Tkachenko SE, Khvat A, et al. From anti-allergic to anti-Alzheimer's: molecular pharmacology of dimebon. Curr Alzheimer Res. 2010; 7(2): 97-112.
42. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261-276. (Pubitemid 18039085)
43. Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression-Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003; 416: 16-23.
44. Axelrod BN, Goldman RS, Alphs LD. Validation of 16-item negative symptom assessment. J Psychiatr Res. 1993; 27(3): 253-258. (Pubitemid 23344946)
45. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990; 3: 247-251. (Pubitemid 20228720)
46. Keefe RS, Harvey PD, Goldberg TE, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008; 102(1-3): 108-115.
47. Rubinstein SYa. Experimental Methods of Pathological Psychology. Moscow: Meditsina; 1970 [in Russian].
48. Tiplady B. Continuous attention: Rationale and discriminant validation of a test designed for use in psychopharmacology. Behav Res Methods. 1992; 24: 16-21.
49. Filimonenko YuI, Timofeyev YuI. Wechsler Adult Intelligence Scale: User Manual. St. Petersburg: Imaton; 2000 [in Russian].
50. Soboleva TV. Use of Proof Assay of Bourdohn-Anfimov for Vocational Guidance: User Manual. Yaroslavl: Tsentr ''Resurs''; 1999 [in Russian].
51. Fleischhacker WW, Heikkinen ME, OliéJP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010; 13(8): 1115-1125.
52. Posner MI, Rothbart MK. Research on attention networks as a model of the integration of psychological science. Annu Rev Psychol. 2007; 58: 1-23.